Association Between Sociodemographic Marginalization and Combination Therapy for Metastatic Hormone-Sensitive Prostate Cancer: Population-Based Cohort Study in Ontario, Canada
Despite universal health care, access to combination therapy for mHSPC remains inequitable, particularly among patients living in marginalized, rural, and/or low-income communities. These disparities underscore the need for equity-driven policy interventions to ensure that all patients with mHSPC benefit from life-prolonging treatment advances.
Authors
- Rodney H. Breau (ORCID: https://orcid.org/0000-0003-2344-9022)
- Aly-Khan Lalani
- Laura C. Rosella (ORCID: https://orcid.org/0000-0003-4867-869X)
- Khatereh Aminoltejari
- Amanda Hird (ORCID: https://orcid.org/0000-0002-2549-6079)
- Soumyajit Roy (ORCID: https://orcid.org/0000-0002-4888-6117)
- Bobby Shayegan
- Quoc-Dien Trinh
- Christopher J.D. Wallis
- Raj Satkunasivam
- Girish S. Kulkarni
- Scott C. Morgan
- David-Dan Nguyen
Institutions
- Mount Sinai Hospital (CA)
- Sunnybrook Health Science Centre (CA)
- University of Pittsburgh (US)
- University of Toronto (CA)
- Juravinski Cancer Centre (CA)
- Ottawa Hospital (CA)
- Princess Margaret Cancer Centre (CA)
- Methodist Hospital (US)
- University Hospitals Seidman Cancer Center (US)
- Public Health Ontario (CA)
- Case Western Reserve University (US)
- St. Joseph’s Healthcare Hamilton (CA)
- McMaster University (CA)
Publication Details
- Journal
- JCO Oncology Practice
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1200/op-25-00766
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00